论文部分内容阅读
临床上用放射标记单克隆抗体治疗转移乳腺癌时,所引起的骨髓抑制从一开始就限制了用药剂量。作者曾给病人输入动员的周围血干细胞以减轻放射免疫治疗所带来的毒性。从经过多次治疗的病人身上难以获得足够的前体细胞,对接受放射免疫治疗的转移乳腺癌病人周围血干细胞动员结果及临床表现与接受大剂量化疗和干细胞移植的转移乳腺癌病人进行了对照研究。
In the treatment of metastatic breast cancer with radiolabeled monoclonal antibodies in clinical practice, the resulting bone marrow suppression limits the dose from the outset. The authors used to input mobilized peripheral blood stem cells to reduce the toxicity of radioimmunotherapy. It is difficult to obtain sufficient precursor cells from patients undergoing multiple treatments. The mobilization results and clinical manifestations of peripheral blood stem cells in patients with metastatic breast cancer undergoing radioimmunotherapy are compared with metastatic breast cancer patients receiving high-dose chemotherapy and stem cell transplantation. the study.